Table S1. Outcome of study review and study selection

Study eTrack number / NCT number	Study abbreviated title	Inclusion/exclusion with rationale
263855/002 / NCT01267058	Tdap-002	Included. Immunogenicity and safety data for the Tdap group only
106316 / NCT00346073	Tdap0.3-007	Included. Immunogenicity and safety data for the Tdap group only
106323 / NCT00385255	Tdap0.3-008	Included. Immunogenicity and safety data for the sequential administration group only and for both the primary cohort and the exploratory cohort of adults aged 65 and older
111413 / NCT00835237	Tdap0.3-011	Included. Immunogenicity and safety data for the Tdap group only
116887 / NCT02052596	Zoster-042	Included. Immunogenicity and safety for the sequential administration group only
263855/028	Tdap-028	Excluded. Too low number of participants using treatment for obstructive airway diseases
263855/034 / NCT01294605	Tdap-034	Excluded. Too low number of participants using treatment for obstructive airway diseases
201532 / NCT03311659	Tdap-050	Excluded. Too low number of participants using treatment for obstructive airway diseases
711866/003 / NCT01277705	Tdap-IPV-003	Excluded. Too low number of participants using treatment for obstructive airway diseases

Tdap, GSK's reduced-antigen tetanus-diphtheria-acellular pertussis vaccine; Tdap-IPV, GSK's reduced-antigen tetanus-diphtheria-acellular pertussis-inactivated poliovirus vaccine.

The studies included in the meta-analysis were conducted in the United States (US) or Australia. Tdap is produced in 2 different formulations, 1 for use in the US, 1 outside the US. The 2 formulations contain the same amounts of each antigen, but the non-US formulation contains a higher amount of aluminum (0.3 mg $Al(OH)_3$ + 0.2 mg $AlPO_4$) than the US formulation (0.3 mg $Al(OH)_3$).